Evidence map›Paper›PMID 41774425›Full record

ArticleCardiovascular intervention and therapeutics2026

Cardiac damage stages and prognosis in patients with bicuspid versus tricuspid aortic valve: insights from the CURRENT AS Registry-2.

Wataru Saitoh, Tomohiko Taniguchi, Yasuaki Takeji, Takeshi Morimoto, Shinichi Shirai, Kenji Ando, Ryosuke Murai, Kohei Osakada, Kotaro Takahashi, Tomohisa Tada and 28 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Wataru SaitohCardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.ORCID http://orcid.org/0009-0002-7803-3323
Tomohiko TaniguchiDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Yasuaki TakejiDepartment of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Takeshi MorimotoDepartment of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan.
Shinichi ShiraiDepartment of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Kenji AndoDepartment of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Ryosuke MuraiDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Kohei OsakadaDepartment of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Kotaro TakahashiDepartment of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.
Tomohisa TadaDepartment of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan.
Koichiro MurataDepartment of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Yuki ObayashiDepartment of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
Masashi AmanoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Takeshi KitaiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Chisato IzumiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Shojiro TatsushimaDepartment of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Norio KanamoriDepartment of Cardiology, Shimada General Medical Center, Shimada, Japan.
Makoto MiyakeDepartment of Cardiology, Tenri Hospital, Tenri, Japan.
Hiroyuki NakayamaHyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Masayasu IzuharaDepartment of Cardiology, Kishiwada City Hospital, Kishiwada, Japan.
Kazuya NagaoDepartment of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
Kenji NakatsumaDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.
Moriaki InokoCardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Eisaku NakaneCardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Hiroki FukudaCardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Yuhei YamajiCardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Mariko KitanoCardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Hideyuki HayashiDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Masahiro KimuraDepartment of Cardiology, Koto Memorial Hospital, Higashiomi, Japan.
Mitsuru IshiiDepartment of CardiologyNational Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Shunsuke UsamiDepartment of Cardiology, Kansai Electric Power Hospital, Osaka, Japan.
Fumiko NakazekiDepartment of Cardiology, Japanese Red Cross Otsu Hospital, Otsu, Japan.
Manabu ShirotaniDepartment of Cardiology, Kindai University Nara Hospital, Ikoma, Japan.
Yasutaka InuzukaDepartment of Cardiology, Shiga General Hospital, Moriyama, Japan.
Koh OnoDepartment of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
Kenji MinatoyaDepartment of Cardiovascular Surgery, Kyoto University Hospital, Kyoto, Japan.
Takeshi KimuraDepartment of Cardiology, Hirakata Kohsai Hospital, Hirakata, 573-0153, 1-2-1 Fujisaka Higashi-machi, Japan. taketaka@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-5665-4076
CURRENT AS Registry-2 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac damage staging is a validated predictor of outcomes in tricuspid aortic valve aortic stenosis (TAV-AS), but its role in bicuspid aortic valve aortic stenosis (BAV-AS) remains unclear. We compared baseline characteristics, cardiac damage stages, and clinical outcomes between BAV-AS and TAV-AS patients. We analyzed 3365 patients with severe aortic stenosis (AS) from the CURRENT AS Registry-2, including 222 with BAV-AS and 3143 with TAV-AS. Cardiac damage stages were classified based on index echocardiographic findings. The primary outcome was a composite of death or heart failure hospitalization. BAV-AS patients were significantly younger and had fewer cardiovascular comorbidities than TAV-AS patients. Despite greater AS severity, BAV-AS patients more often presented with less advanced cardiac damage (stage 0–1: 53% versus 29%, P < 0.001). Among patients aged < 75 years, early-stage cardiac damage was more prevalent in BAV-AS, whereas TAV-AS patients aged < 75 years showed higher rates of advanced cardiac damage. The cumulative 3-year incidence of the primary outcome was significantly lower in BAV-AS than in TAV-AS (9.9% versus 38.4%, P < 0.001). Adjusted analysis confirmed that BAV-AS remained significantly associated with better outcome (hazard ratio: 0.53, 95% confidence interval: 0.33–0.86, P = 0.01). BAV-AS patients exhibited more favorable baseline profiles, less advanced cardiac damage, and better prognosis despite greater AS severity, highlighting the prognostic value of cardiac damage staging irrespective of valve morphology.

Indexed as

Aortic ValveAortic Valve StenosisBicuspid Aortic Valve DiseaseTricuspid ValveAgedAged, 80 and overEchocardiographyFemaleHumansMalePrognosisRegistriesSeverity of Illness IndexAortic stenosisAortic valve replacementPrognosis

Identifiers

PMID41774425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.